Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 10/20 | 0.34 |
| ▸ | SYK | P43405 | 9/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.34 |
| ▸ | CDK2 | P24941 | 4/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | ITK | Q08881 | 3/20 | 0.34 |
| ▸ | PLK4 | O00444 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | INSR | P06213 | 2/20 | 0.34 |
| ▸ | LCK | P06239 | 2/20 | 0.34 |
| ▸ | FYN | P06241 | 2/20 | 0.34 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | CSF1R | P07333 | 2/20 | 0.34 |
| ▸ | LYN | P07948 | 2/20 | 0.34 |
| ▸ | ROS1 | P08922 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | FLT1 | P17948 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115640 | 1.00 | AURKA (0.34) | AURKASYKAURKBCDK2JAK2 | |
| SCHEMBL1115978 | 0.93 | SYK (0.38) | AURKASYKAURKBCDK2JAK2 | |
| SCHEMBL1116016 | 0.93 | SYK (0.38) | AURKASYKAURKBCDK2JAK2 | |
| SCHEMBL1115820 | 0.90 | SYK (0.32) | AURKASYKAURKBCDK2JAK2 | |
| SCHEMBL1115583 | 0.89 | CDK7 (0.36) | AURKASYKAURKBCDK2JAK2 | |
| SCHEMBL1115590 | 0.89 | CDK7 (0.36) | AURKASYKAURKBCDK2JAK2 | |
| SCHEMBL1115635 | 0.88 | CDK9 (0.34) | AURKASYKAURKBCDK2JAK2 | |
| SCHEMBL1115639 | 0.88 | CDK9 (0.34) | AURKASYKAURKBCDK2JAK2 | |
| SCHEMBL1115818 | 0.87 | CDK7 (0.32) | SYKEGFRCDK7CDK9BTK | |
| SCHEMBL1115763 | 0.85 | AURKA (0.38) | AURKAAURKBCDK2CDK1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193197-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | claimed |
| EP-2089369-B1 | 2,4 -PYRIMIDINEDIAMINE DERIVATIVES AS INHIBITORS OF JAK KINASES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | RIGEL PHARMACEUTICALS INC (US) | 2011-02-02 | — | — | EP | claimed |
| EP-2089369-A2 | 2,4 -PYRIMIDINEDIAMINE DERIVATIVES AS INHIBITORS OF JAK KINASES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Rigel Pharmaceuticals, Inc. (US) | 2009-08-19 | — | — | EP | claimed |
| US-20080194603-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | claimed |
| WO-2008049123-A2 | 2,4-PYRIMIDINEDIAMINE DERIVATIVES AS INHIBITORS OF JAK KINASES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | WO | claimed |
| US-9040543-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140234333-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8729087-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120213795-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | disclosed |
| US-8193197-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2089369-B1 | 2,4 -PYRIMIDINEDIAMINE DERIVATIVES AS INHIBITORS OF JAK KINASES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | RIGEL PHARMACEUTICALS INC (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-2089369-A2 | 2,4 -PYRIMIDINEDIAMINE DERIVATIVES AS INHIBITORS OF JAK KINASES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Rigel Pharmaceuticals, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20080194603-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008049123-A2 | 2,4-PYRIMIDINEDIAMINE DERIVATIVES AS INHIBITORS OF JAK KINASES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234333-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK2, JAK1, JAK3 | AURKA 590/4885SYK 42/4885AURKB 343/4885 |
| US-20120213795-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK2, JAK1, JAK3 | AURKA 590/4885SYK 42/4885AURKB 343/4885 |
| US-20080194603-A1 | Prevent transplant rejection; autoimmune diseases | JAK1, JAK3, JAK2 | AURKA 3390/4885SYK 162/4885AURKB 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.